CD19 and prostate carcinoma: One trial is targeting PMSA in prostate cancer (NCT04633148), while another ALL study (NCT03398967) utilised a UniCAR that targets either CD19/20 or CD19/22 with complete remission in >80% of refractory ALL patients after 28 days [162].